Vaccine-Preventable Bacterial Diseases

Vaccine-preventable bacterial diseases are infections caused by bacteria for which effective vaccines exist — including diphtheria, tetanus, pertussis, invasive Haemophilus influenzae type b disease, invasive pneumococcal disease, and meningococcal disease. This topic describes the group as a category, including the toxin-based and capsular-polysaccharide approaches that distinguish many bacterial vaccines from viral ones.

Definition

Vaccine-preventable bacterial diseases are communicable diseases caused by bacteria against which a licensed, effective vaccine is available, considered together as a class within vaccine-preventable diseases.

Scope

The topic surveys bacterial diseases that immunization can prevent, the antigenic targets used in their vaccines (toxoids and capsular polysaccharides, often protein-conjugated), and the epidemiologic effects observed after vaccine introduction, including reductions in invasive disease and, for conjugate vaccines, effects on carriage. It is a reference-level description, not clinical or schedule guidance.

Core questions

• Which bacterial diseases are preventable by currently available vaccines?
• How do toxoid and conjugate vaccine strategies differ from viral vaccine approaches?
• How have conjugate vaccines changed the epidemiology of invasive Hib, pneumococcal, and meningococcal disease?
• What is the role of nasopharyngeal carriage and replacement in bacterial VPD dynamics?

Key concepts

• Toxoid vaccines (diphtheria, tetanus)
• Capsular polysaccharide and protein-conjugate vaccines
• Invasive bacterial disease as the prevented outcome
• Nasopharyngeal carriage and its reduction by conjugate vaccines
• Serotype/serogroup replacement
• Non-transmissible exception: tetanus (environmental, not person-to-person)

Mechanisms

Bacterial vaccines target different components depending on the pathogen. For diphtheria and tetanus, the disease is driven by toxins, and inactivated toxins (toxoids) elicit neutralizing antibodies. For encapsulated bacteria such as Haemophilus influenzae type b, Streptococcus pneumoniae, and Neisseria meningitidis, the protective antigen is the capsular polysaccharide; conjugating it to a carrier protein converts a weak, T-cell-independent response into a robust, memory-forming one effective in young children. Conjugate vaccines also reduce nasopharyngeal carriage of vaccine serotypes, which lowers transmission and can protect unvaccinated people, though non-vaccine serotypes can partially replace those removed.

Clinical relevance

Understanding the bacterial VPDs and their vaccine strategies supports public-health literacy and evidence appraisal. The marked falls in invasive Hib and pneumococcal disease following conjugate-vaccine introduction characterize the epidemiology of these diseases; this entry is descriptive and is not a basis for individual immunization decisions.

Epidemiology

Introduction of conjugate vaccines was followed by large declines in invasive disease: invasive Haemophilus influenzae type b disease in young children fell dramatically in countries that adopted routine Hib vaccination, and invasive pneumococcal disease due to vaccine serotypes declined after pneumococcal conjugate vaccine introduction, partly offset over time by serotype replacement. Toxin-mediated diseases such as diphtheria and tetanus also fell sharply with widespread toxoid use, though tetanus, acquired from the environment rather than person-to-person, does not benefit from herd immunity.

Evidence & guidelines

The evidence is largely observational and program-based, including population cohort and surveillance studies of invasive disease before and after vaccine introduction, such as Hviid and Melbye on Hib and Peckeu and colleagues on pneumococcal conjugate vaccine impact. Disease-specific recommendations are issued by national immunization advisory bodies and WHO position papers; this entry references them for orientation and does not provide individualized guidance.

History

Diphtheria and tetanus toxoids, developed in the early twentieth century, were among the first bacterial vaccines, later combined with pertussis vaccine. The major modern advance was the conjugate vaccine: linking capsular polysaccharide to a carrier protein, first realized for Haemophilus influenzae type b in the late 1980s and extended to pneumococcal and meningococcal vaccines, which together reshaped the epidemiology of invasive bacterial disease in children.

Key figures

• Stanley Plotkin
• John Robbins
• Rachel Schneerson

Seminal works

• hviid-2004
• peckeu-2021
• plotkin-2018

Frequently asked questions

Why are many bacterial vaccines 'conjugate' vaccines?

The protective targets on encapsulated bacteria are polysaccharides, which on their own provoke a weak response in young children; conjugating them to a carrier protein recruits T-cell help, producing a strong, memory-forming response and reducing carriage.

Does vaccinating against tetanus protect the community?

No. Tetanus is acquired from environmental spores rather than from other people, so it is not transmitted person-to-person and does not benefit from herd immunity; protection depends on individual immunization.